Pharma channel feed – Endpoints News

Pharma channel feed

An employee complaint at Eli Lilly's Branchburg plant alleges altered quality control docs amid FDA probe — report

5 years ago

ChemoCentryx plunges as FDA raises questions about rare disease drug ahead of adcomm

5 years ago

Merck lays out vision for women's health spinout Organon, with some special plans for its $9B windfall

5 years ago

Regeneron’s golden goose Eylea may stave off biosimilar competition until 2024 or beyond

5 years ago

The Covid-19 pandemic can't hold down global drug spending, IQVIA reports, with cash expected to keep flowing

5 years ago

Biogen won’t explain why FDA slapped down their bid for new Tysabri formulation

5 years ago

Bristol Myers' Opdivo scores priority review in common bladder cancer, marking latest win in PD-1 battle with Keytruda

5 years ago

AstraZeneca's non-profit vaccine is, for now, costing them money

5 years ago

More info on drug review timelines? HHS and FDA pull Trump HHS’ last-minute pledge

5 years ago

Bobbing on a sea of crises, bluebird's Nick Leschly sees his pay cut in half as the biotech prepares to split

5 years ago

House committee to grill AbbVie CEO next month on suppressing Humira competition

5 years ago

Merck, Roche and Bristol Myers nab 4 of 6 positive ODAC votes for ‘dangling’ accelerated approvals

5 years ago

Ken Frazier ends his 29-year tenure at Merck on a sour note, revealing a dip in sales in his final earnings call

5 years ago

Staring at a down quarter for Opdivo, Bristol Myers keeps its eyes on price competition potential in packed PD-1 market

5 years ago

Sanofi is expanding at light speed abroad, but it's leaving behind a Pennsylvania plant and its 75 employees

5 years ago

ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

5 years ago

The pressure builds for Emma Walmsley as GlaxoSmithKline misses Q1 projection, drops more cancer drugs

5 years ago

Opinion: Meaningful drug pricing reforms are headed nowhere fast

5 years ago

Sanofi reports sales growth amid Dupixent's China launch, but reveals PDUFA delay in Pompe disease program

5 years ago

Eli Lilly shares take a hit as company lowers full-year forecast

5 years ago

Patient deaths force Astellas to write off $540M of their $3B gene therapy buyout as timeline grows and target group shrinks

5 years ago

Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market

5 years ago

Biogen reverses course on compassionate use for ALS drug tofersen with plans to open program in July

5 years ago

Regeneron's Len Schleifer, George Yancopoulos start their ambitious 5-year plan, earning a front-loaded $270M combined

5 years ago

First page Previous page 241 242 243244245 246 247 Next page Last page